



MEDIA CONTACT:

Lisa Kornblatt
SS|PR
847-415-9330
lkornblatt@sspr.com

InVivo Therapeutics to Present at the Fourth Annual BioTech Showcase 2012

Company to Showcase Latest Advances in Spinal Cord Injury Treatment at Industry's Largest Annual Healthcare Investor Conference

CAMBRIDGE, Mass. – January 4, 2012 – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for the [treatment of spinal cord injuries](#) (SCI), today announced CEO Frank Reynolds will present InVivo's most recent breakthroughs and provide a business update to potential investors during the [Fourth Annual BioTech Showcase](#). The conference is scheduled for January 9-11th at the Parc 55 Wyndham in San Francisco.

Reynolds is scheduled to present and participate in the Regenerative Medicine Insight Track on Tuesday, January 10th from 1:30-3:00 pm PST in the section on CNS, Ophthalmology and Spinal Injury. Frank will present an overview of InVivo's innovative biomaterial scaffold technology. The company is currently awaiting FDA approval to move forward with its first human clinical study for acute SCI treatment using its proprietary scaffold to provide structural support to a damaged spinal cord to help prevent paralysis and improve recovery and prognosis for patients. The pilot study is expected to begin in 2012.

In addition, both Reynolds and InVivo's Director of Finance, Sean Moran, will be available throughout the event for one-on-one meetings with investors by appointment only. To schedule a meeting, registered attendees can submit a meeting request through the conference website (<http://www.ebdgroup.com/bts/partnering/index.php>).

The BioTech Showcase is a forum devoted to enable private and public life science companies the opportunity to present to an audience of investors and business development executives. Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-on-one partnering meeting and networking.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the

company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

#